SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Risk for dementia reduced in association with antihypertensive use
Sep 13, 2023
An individual patient data meta-analysis shows increased risk for dementia for those with untreated hypertension.
DOACs reduce dementia risk versus warfarin in A-Fib
Sep 07, 2023
Significant reductions were seen in dementia risk for rivaroxaban, apixaban and dabigatran versus warfarin in a network meta-analysis.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...